980 reports of this reaction
1.9% of all ANASTROZOLE TABLETS reports
#9 most reported adverse reaction
MALIGNANT NEOPLASM PROGRESSION is the #9 most commonly reported adverse reaction for ANASTROZOLE TABLETS, manufactured by Avet Pharmaceuticals Inc. There are 980 FDA adverse event reports linking ANASTROZOLE TABLETS to MALIGNANT NEOPLASM PROGRESSION. This represents approximately 1.9% of all 50,885 adverse event reports for this drug.
Patients taking ANASTROZOLE TABLETS who experience malignant neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT NEOPLASM PROGRESSION is a less commonly reported adverse event for ANASTROZOLE TABLETS, but still significant enough to appear in the safety profile.
In addition to malignant neoplasm progression, the following adverse reactions have been reported for ANASTROZOLE TABLETS:
The following drugs have also been linked to malignant neoplasm progression in FDA adverse event reports:
MALIGNANT NEOPLASM PROGRESSION has been reported as an adverse event in 980 FDA reports for ANASTROZOLE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT NEOPLASM PROGRESSION accounts for approximately 1.9% of all adverse event reports for ANASTROZOLE TABLETS, making it a notable side effect.
If you experience malignant neoplasm progression while taking ANASTROZOLE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.